Cargando…
Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients
Background: Acute kidney injury (AKI) is highly prevalent in critical COVID-19 patients. The diagnosis and staging of AKI are based on serum creatinine (sCr) and urinary output criteria, with limitations in the functional markers. New cell-cycle arrest biomarkers [TIMP2]*[IGFBP7] have been proposed...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857893/ https://www.ncbi.nlm.nih.gov/pubmed/36673127 http://dx.doi.org/10.3390/diagnostics13020317 |
_version_ | 1784873962104160256 |
---|---|
author | Greco, Massimiliano De Rosa, Silvia Boehm, Fabian Spano, Sofia Aceto, Romina Voza, Antonio Reggiani, Francesco Calatroni, Marta Castellani, Gianluca Costantini, Elena Villa, Gianluca Cecconi, Maurizio |
author_facet | Greco, Massimiliano De Rosa, Silvia Boehm, Fabian Spano, Sofia Aceto, Romina Voza, Antonio Reggiani, Francesco Calatroni, Marta Castellani, Gianluca Costantini, Elena Villa, Gianluca Cecconi, Maurizio |
author_sort | Greco, Massimiliano |
collection | PubMed |
description | Background: Acute kidney injury (AKI) is highly prevalent in critical COVID-19 patients. The diagnosis and staging of AKI are based on serum creatinine (sCr) and urinary output criteria, with limitations in the functional markers. New cell-cycle arrest biomarkers [TIMP2]*[IGFBP7] have been proposed for early detection of AKI, but their role in critically ill COVID-19 patients is poorly understood. Methods: We conducted an observational study to assess the performance of [TIMP2]*[IGFBP7] for the detection of AKI in critical COVID-19 patients admitted to our intensive care unit (ICU). We sampled urinary [TIMP2]*[IGFBP7] levels at ICU admission, 12 h, 24 h, and 48 h, and compared the results to the development of AKI, as well as baseline and laboratory data. Results: Forty-one patients were enrolled. The median age was 66 years [57–72] and most were males (85%). Thirteen patients (31.7%) developed no/mild stage AKI, 19 patients (46.3%) moderate AKI, and nine patients (22.0%) severe AKI. The ICU mortality was 29.3%. sCr levels in the Emergency Department or at ICU admission were not significantly different according to AKI stage. [TIMP-2]*[IGFBP-7] urinary levels were elevated in severe AKI at 12 h after ICU admission, but not at ICU admission or 24 h or 48 h after ICU admission. Conclusion: Urinary biomarkers [TIMP-2]*[IGFBP-7] were generally increased in this population with a high prevalence of AKI, and were higher in patients with severe AKI measured at 12 h from ICU admission. Further studies are needed to evaluate the best timing of these biomarkers in this population. |
format | Online Article Text |
id | pubmed-9857893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98578932023-01-21 Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients Greco, Massimiliano De Rosa, Silvia Boehm, Fabian Spano, Sofia Aceto, Romina Voza, Antonio Reggiani, Francesco Calatroni, Marta Castellani, Gianluca Costantini, Elena Villa, Gianluca Cecconi, Maurizio Diagnostics (Basel) Article Background: Acute kidney injury (AKI) is highly prevalent in critical COVID-19 patients. The diagnosis and staging of AKI are based on serum creatinine (sCr) and urinary output criteria, with limitations in the functional markers. New cell-cycle arrest biomarkers [TIMP2]*[IGFBP7] have been proposed for early detection of AKI, but their role in critically ill COVID-19 patients is poorly understood. Methods: We conducted an observational study to assess the performance of [TIMP2]*[IGFBP7] for the detection of AKI in critical COVID-19 patients admitted to our intensive care unit (ICU). We sampled urinary [TIMP2]*[IGFBP7] levels at ICU admission, 12 h, 24 h, and 48 h, and compared the results to the development of AKI, as well as baseline and laboratory data. Results: Forty-one patients were enrolled. The median age was 66 years [57–72] and most were males (85%). Thirteen patients (31.7%) developed no/mild stage AKI, 19 patients (46.3%) moderate AKI, and nine patients (22.0%) severe AKI. The ICU mortality was 29.3%. sCr levels in the Emergency Department or at ICU admission were not significantly different according to AKI stage. [TIMP-2]*[IGFBP-7] urinary levels were elevated in severe AKI at 12 h after ICU admission, but not at ICU admission or 24 h or 48 h after ICU admission. Conclusion: Urinary biomarkers [TIMP-2]*[IGFBP-7] were generally increased in this population with a high prevalence of AKI, and were higher in patients with severe AKI measured at 12 h from ICU admission. Further studies are needed to evaluate the best timing of these biomarkers in this population. MDPI 2023-01-15 /pmc/articles/PMC9857893/ /pubmed/36673127 http://dx.doi.org/10.3390/diagnostics13020317 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Greco, Massimiliano De Rosa, Silvia Boehm, Fabian Spano, Sofia Aceto, Romina Voza, Antonio Reggiani, Francesco Calatroni, Marta Castellani, Gianluca Costantini, Elena Villa, Gianluca Cecconi, Maurizio Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients |
title | Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients |
title_full | Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients |
title_fullStr | Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients |
title_full_unstemmed | Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients |
title_short | Kinetics of the Cell Cycle Arrest Biomarkers (TIMP2 and IGFBP7) for the Diagnosis of Acute Kidney Injury in Critically Ill COVID-19 Patients |
title_sort | kinetics of the cell cycle arrest biomarkers (timp2 and igfbp7) for the diagnosis of acute kidney injury in critically ill covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857893/ https://www.ncbi.nlm.nih.gov/pubmed/36673127 http://dx.doi.org/10.3390/diagnostics13020317 |
work_keys_str_mv | AT grecomassimiliano kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT derosasilvia kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT boehmfabian kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT spanosofia kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT acetoromina kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT vozaantonio kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT reggianifrancesco kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT calatronimarta kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT castellanigianluca kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT costantinielena kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT villagianluca kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients AT cecconimaurizio kineticsofthecellcyclearrestbiomarkerstimp2andigfbp7forthediagnosisofacutekidneyinjuryincriticallyillcovid19patients |